MLND 1.49$ (-69%)
Entwicklung von Livoletide (PWS) wird gestoppt
"The decision to discontinue the PWS program was based on topline data from the pivotal Phase 2b ZEPHYR study which showed that treatment with livoletide did not result in a statistically significant improvement in hyperphagia and food-related behaviors as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) compared to placebo."
https://investors.millendo.com/news-releases/...ults-pivotal-phase-2b
- 2019-er Verlust 45 Mio. $ (~11 Mio. $ pro Quartal)
- Cash 65 Mio. $
- EK 60 Mio. $
- Total Assets 75 Mio. $
Verkauf oder Merger? Millendo vor ungewisser Zukunft
- Q3/20 Cash ~44 Mio. $
- Q3/20 Schulden ~9 Mio. $
- MK 30 Mio. $
- Cash-Burn pro Quartal 6-7 Mio. $ (geschätzt)
https://investors.millendo.com/news-releases/...er-2020-operating-and
Die einzige verbleibende Frühphasenstudie für ihren NK3R-Antagonisten MLE-301 wird geschlossen.
https://endpts.com/...feat-and-a-last-search-for-a-way-to-end-things/
https://investors.millendo.com/news-releases/...e-and-business-update
Merger mit Tempest Therapeutics
https://www.benzinga.com/general/biotech/21/03/...therapeutics-merger
"The merger is expected to close in the first half of this year, with Millendo stockholders expected to own approximately 18.5% of the combined company and pre-merger Tempest stockholders to hold 81.5%."
https://endpts.com/...up-for-a-late-stage-study-in-migraine-patients/
- Merger zwischen Tempest Therapeutics und Millendo Therapeutics abgeschlossen
- Millendo 1/15 RS
- neues Kürzel TPST (13,10$) -18%
https://ir.tempesttx.com/news-releases/...nd-completes-pipe-financing
https://ir.tempesttx.com/news-releases/...-2021-financial-results-and
Zahlen für Q2/22
- keine Umsätze
- Verlust 9 Mio. $
- Cash 52 Mio. $
- MK 16 Mio. $
- extended Tempest’s runway into the first quarter of 2024
https://ir.tempesttx.com/news-releases/...-2022-financial-results-and
Zahlen für Q3/22
- keine Umsätze
- Verlust 8,9 Mio. $
- Cash 43 Mio. $
- MK 13 Mio. $
https://ir.tempesttx.com/news-releases/...-2022-financial-results-and
Zahlen für FY22
- keine Umsätze
- Verlust 36 Mio. $
- Cash 31 Mio. $
- MK 25 Mio. $
- to fund operations through the second quarter of 2024
https://ir.tempesttx.com/news-releases/...ancial-results-and-provides
Zahlen für Q1/23
- keine Umsätze
- Verlust 7,6 Mio. $
- Cash 23 Mio. $
- MK 22 Mio. $
- to fund operations through the second quarter of 2024
https://ir.tempesttx.com/news-releases/...-2023-financial-results-and
Zahlen für Q2/23
- kein Umsatz
- Verlust 7,6 Mio. $
- Cash 18 Mio. $
- MK 7 Mio. $
https://ir.tempesttx.com/news-releases/...-2023-financial-results-and